论文部分内容阅读
目前,垂体瘤可以在局限于蝶鞍内的微腺瘤阶段得到确诊,并采用经蝶窦显微手术,选择地将肿瘤全部摘除。然而,就全部垂体瘤来说,手术远非可以解决一切问题。50多年前,Cushing曾预言:目前垂体瘤的手术治疗,实际上是处于本病治疗发展史的石器时代,不久,生物化学家将告诉我们,如何治愈最普遍的功能性垂体腺瘤。现在麦角碱的衍生物、多巴胺增效剂——溴隐亭,成功地治疗垂体腺瘤的事实,有力地证明了这位医学大师的预言。新近,关于溴隐亭治疗功能性垂体腺瘤的报导,说明溴隐亭的问世,确是垂体瘤治疗上的一大重要进展。一、溴隐亭能迅速地降低病人血液中升高的泌乳素浓度,使之恢复正常。放射免疫分析的研究表明,大部分垂体腺瘤分泌泌乳素(PRL)。以往称之为非分泌的难染色性腺瘤,实际上2/3是属于PRL腺
At present, pituitary adenomas can be diagnosed at the stage of microadenomas in the sella, and transsphenoidal microsurgery is used to selectively remove all the tumors. However, for all pituitary tumors, surgery is far from solving all problems. More than 50 years ago, Cushing predicted that the surgical treatment of pituitary adenomas is actually in the stone age of the treatment history of the disease. Soon, biochemists will tell us how to cure the most common functional pituitary adenomas. The fact that ergotamine derivatives, the dopamine potentiator, bromocriptine, is now successfully treated in pituitary adenomas is a powerful testimony to the medical scientist’s prediction. Recently, reports on the treatment of functional pituitary adenomas with bromocriptine showed that the advent of bromocriptine is indeed an important progress in the treatment of pituitary tumors. 1. Bromocriptine can rapidly reduce the elevated concentration of prolactin in the patient’s blood and return it to normal. Radioimmunoassay studies have shown that most pituitary adenomas secrete prolactin (PRL). Previously referred to as non-secreting hard-to-stain adenomas, actually two-thirds of them belong to PRL glands.